AK102

DRUG7 trials

Sponsors

Akeso

Conditions

Heterozygous Familial HypercholesterolemiaHomozygous Familial HypercholesterolemiaHypercholesterolaemiaHypercholesterolemiaHyperlipidemia

Phase 1

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

CompletedNCT04169386

AkesoHypercholesterolaemia

Start: 2018-05-23End: 2018-11-22Updated: 2025-02-28

Phase 2

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

CompletedNCT03933293

AkesoHomozygous Familial Hypercholesterolemia

Start: 2019-05-13End: 2021-03-15Updated: 2023-03-02

A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

CompletedNCT04173793

AkesoHeterozygous Familial Hypercholesterolemia

Start: 2019-11-18End: 2022-09-26Updated: 2023-03-02

A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia

CompletedNCT04358432

AkesoHypercholesterolemia

Start: 2020-05-13End: 2021-02-25Updated: 2023-03-02

Phase 3

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

CompletedNCT05255458

AkesoHyperlipidemia

Start: 2021-11-04End: 2023-01-09Updated: 2025-02-28

A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

CompletedNCT05255094

AkesoHyperlipidemia

Start: 2021-11-03End: 2022-06-22Updated: 2025-03-06

A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

CompletedNCT05260411

AkesoHyperlipidemia

Start: 2022-01-26End: 2022-12-19Updated: 2025-03-06